Funding Round
INBRAIN Neuroelectronics secures €40M Series C for graphene DBS clinical program
EU-Startups4/20/2026·04/20/26🌐 Europe
Summary
Barcelona-based INBRAIN Neuroelectronics closed a €40M Series C led by EQT Life Sciences with Kurma Partners. The round follows their first-in-human graphene electrode trial at Hospital Clínic Barcelona and will fund their Phase 1 graphene DBS trial in Parkinson's disease and epilepsy patients across three European centers.
Why it matters
INBRAIN is the most advanced graphene neural interface company in the world. A €40M Series C positions them to generate the human DBS data needed for CE mark application, with a potential first regulatory approval for graphene-based implants within 4 years.
#BCI#Deep Brain Stimulation#Neural Interfaces#Neurostimulation
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in